Syngene International Limited
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
What Syngene files
- Investor Meet96
- Others83
- Important38
- Updates17
- Board Meeting13
- PPTs10
Syngene International granted 1,426,061 Performance Share Units (PSUs) to employees. This incentive plan allows conversion to shares at Rs. 10 per PSU after a 3-year vesting. It aligns employee interests with company growth but will lead to equity dilution.
Syngene International's Managing Director & CEO, Peter Bains, has resigned, initiating a leadership transition. He will ensure a smooth handover. Investors will watch for clarity on future leadership direction.
Syngene paid fines of Rs 23,600 each to NSE & BSE for Nomination & Remuneration Committee composition non-compliance. The Board addressed the issue, paid fines, and is strengthening processes to ensure future compliance. Focus on robust governance.
Syngene's Board has approved an updated policy for fair disclosure of market-sensitive information. This strengthens internal governance and compliance regarding how the company shares important, unpublished data.
Syngene International granted 5,26,615 Performance Share Units (PSUs) to eligible employees. These PSUs vest after a three-year performance period, converting into equity shares at Rs. 10 each. This move aims to incentivize employees and implies potential future share dilution.